Azilsartan medoxomil: Angiotensin receptor blocker in the treatment of hypertension.
Artículo
en Inglés
| IMSEAR
| ID: sea-178388
ABSTRACT
Hypertension is an important risk factor for cardiovascular and renal disease. It’s early detection and control is critically important as it is an important attributable cause of stroke, coronary artery disease, heart failure, atrial fibrillation and ESRD. Recent data indicates increasing prevalence of hypertension amongst various populations. This reflects the importance of having a variety of treatment options for the management of this condition. Angiotensin receptor blockers are highly effective at reducing blood pressure, have excellent tolerability and renoprotective properties, hence they remain a useful choice in the management of hypertension. Azilsartan medoxomil has recently been approved by the FDA for the oral treatment of hypertension making it the eighth Angiotensin receptor blocker to be approved for this indication.
Texto completo:
Disponible
Índice:
IMSEAR (Asia Sudoriental)
Tipo de estudio:
Factores de riesgo
/
Estudio de tamizaje
Idioma:
Inglés
Año:
2013
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS